Mr. Dave Burwell reports

OCUMETICS POISED FOR VALUE-DEFINING GROUP TWO FIRST-IN-HUMAN LENS IMPLANTATIONS

Ocumetics Technology Corp. has completed key clinical milestones and has shared an update on the pending Group Two first-in-human surgeries.

"We couldn't be more excited to be approaching our Group Two patient lens implantations," said Dean Burns, chief executive officer of Ocumetics. "Our global team has worked tirelessly to reach this value-defining milestone, with all clinical, regulatory and manufacturing requirements completed. We are currently finalizing details for patient lens implantations, which are imminent."

"On the premise that Group Two patient results meet or exceed our objectives, as did Group One patient results, our prior discussions with several of the world's largest ophthalmic companies can move to the next stage. We anticipate initial patient results will be in hand by the end of the year, and data necessary to advance potential negotiations with the dominant ophthalmic companies will be available very early in the new year," added Mr. Burns.

Unlike the Group One study, which focused on safety, the primary and secondary purposes of the Group Two lens implantations are to study the safety, distance and near-vision performance of the Ocumetics accommodating intraocular lens.

Over the past several months, Ocumetics has met significant clinical, regulatory and manufacturing milestones:

• Completed manufacturing and testing of the redesigned next-generation Ocumetics lenses, incorporating significant engineering advancements designed to enhance accommodative performance, surgical handling, reliability and manufacturing scalability;
• Confirmed Mexico City clinic for Group Two patient lens implantations;
• Delivered redesigned lens delivery systems to Mexico City clinic;
• Summitted enhanced Group Two clinical protocols to clinic ethics committee;
• Confirmed the Group Two study will evaluate the Ocumetics lens for safety plus near- and distance-vision performance;
• Commenced patient recruitment at Mexico City clinical site;
• Commenced evaluation of Group One 12-month visit results.

Coming clinical activities include:

• Final site initiation and surgeon training immediately prior to the Group Two Ocumetics lens implantations;
• Perform Group Two patient lens implantations;
• Daily, weekly and monthly patient progress monitoring.

Reporting on the results of Group One 12-month follow-up visits will be released shortly.

About Ocumetics Technology Corp.

Ocumetics is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

Ocumetics is in the first-in-human early feasibility study phase of a game-changing technology for the ophthalmic industry. Ocumetics has developed a dynamic intraocular lens that fits within the natural lens compartment of the eye, potentially to eliminate the need for corrective lenses. It is designed to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses, and without perceptible time lag.

We seek Safe Harbor.